EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Growth Differentiation Factor 15 Elevation in the Central Nervous System Is Associated With Failure to Thrive in Alexander Disease

Tracy L Hagemann iD, Michelle M Sonsalla, Cora Luzinski iD, Fernando Zacahua, David A Harris iD, Dudley W Lamming, Albee Messing

Annals of Clinical and Translational Neurology · 2026

DOI: 10.1002/acn3.70209 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Clinical and Translational Neurology, 2026. Verfasst von Tracy L Hagemann und 6 weiteren Autor:innen. Beteiligte Einrichtung: Waisman Center, University of Wisconsin-Madison, Madison, Wisconsin, USA. Hauptthemen laut MEDLINE: Growth Differentiation Factor 15, Alexander Disease, Failure to Thrive, Brain. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIA NIH HHS, NIDDK NIH HHS, BLRD VA.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Alexander disease (AxD) is a severe neurodegenerative disorder caused by gain‐of‐function mutations in the gene for GFAP, which lead to protein aggregation and a primary astrocytopathy. Symptoms vary, but failure to thrive (FTT) and frequent emesis are common and cause significant morbidity. Here we investigate GDF15, a member of the TGFβ superfamily, which regulates energy balance and appetite, as a potential mediator of FTT in AxD.

Methods

In this study, we use the Gfap +/R237H rat model (R237H), in which pups fail to gain weight after weaning and become frail and impaired as they mature, to assess muscle atrophy, energy expenditure, and feeding behavior in AxD. We measure GDF15 in brain and cerebrospinal fluid (CSF), assess activation of its receptor GFRAL in area postrema neurons, and use GFAP suppression to correlate FTT phenotypes with GDF15 expression. Finally, we measure GDF15 in patients with AxD.

Results

R237H rats show reduced lean and fat mass and muscle atrophy despite reduced energy expenditure, and at an early age exhibit pica and anorexia. GDF15 is expressed by R237H rat astrocytes and is elevated in brainstem and CSF, but not in plasma. Neurons expressing GFRAL, a mediator of GDF15‐induced appetite suppression, are activated in the area postrema. Suppression of GFAP using antisense oligonucleotides normalizes weight gain and GDF15 levels in brainstem and CSF. In human AxD, GDF15 is elevated in CSF, but not in blood.

Interpretation

GDF15 is associated with FTT in AxD and provides both a target and useful biomarker for the development of future therapeutics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Growth Differentiation Factor 15Alexander DiseaseFailure to ThriveBrainAnimalsRatsHumansDisease Models, AnimalMaleFemaleGlial Fibrillary Acidic ProteinChildGlial Cell Line-Derived Neurotrophic Factor ReceptorsRats, Transgenic

Stichwörter der Autor:innen

Alexander diseaseGDF15GFAParea postremaastrocyte

Substanzen

Growth Differentiation Factor 15GDF15 protein, humanGlial Fibrillary Acidic ProteinGlial Cell Line-Derived Neurotrophic Factor Receptors

Autor:innen und Institutionen

  • Waisman Center, University of Wisconsin-Madison, Madison, Wisconsin, USA.
  • Department of Medicine, University of Wisconsin-Madison, Madison, Wisconsin, USA.
  • William S. Middleton Memorial Veterans Hospital, Madison, Wisconsin, USA.
  • Comparative Biomedical Sciences Graduate Program, University of Wisconsin-Madison, Madison, Wisconsin, USA.
  • Wisconsin Laboratory for Surgical Metabolism, Department of Surgery, University of Wisconsin-Madison, Madison, Wisconsin, USA.
  • University of Wisconsin Comprehensive Diabetes Center, University of Wisconsin-Madison, Madison, Wisconsin, USA.

ORCID-Profile: Tracy L Hagemann, Cora Luzinski, David A Harris

Förderung

  • NIA NIH HHS
  • NIDDK NIH HHS
  • BLRD VA
  • University of Wisconsin-Madison
  • NCI NIH HHS
  • Department of Surgery
  • NICHD NIH HHS
  • University of Wisconsin Carbone Cancer Center

Zitieren

APA

Hagemann, T. L., Sonsalla, M. M., Luzinski, C., Zacahua, F., Harris, D. A., Lamming, D. W., & Messing, A. (2026). Growth Differentiation Factor 15 Elevation in the Central Nervous System Is Associated With Failure to Thrive in Alexander Disease. Annals of Clinical and Translational Neurology. https://doi.org/10.1002/acn3.70209

Vancouver

Hagemann TL, Sonsalla MM, Luzinski C, Zacahua F, Harris DA, Lamming DW, et al. Growth Differentiation Factor 15 Elevation in the Central Nervous System Is Associated With Failure to Thrive in Alexander Disease. Annals of Clinical and Translational Neurology. 2026. doi:10.1002/acn3.70209

BibTeX
@article{Hagemann2026,
  author = {Hagemann, Tracy L and Sonsalla, Michelle M and Luzinski, Cora and Zacahua, Fernando and Harris, David A and Lamming, Dudley W and Messing, Albee},
  title = {Growth Differentiation Factor 15 Elevation in the Central Nervous System Is Associated With Failure to Thrive in Alexander Disease},
  journal = {Annals of Clinical and Translational Neurology},
  year = {2026},
  doi = {10.1002/acn3.70209}
}
Kostenlos starten →